Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxxinity Inc Cl A (VAXX)

Vaxxinity Inc Cl A (VAXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 38
  • Shares Outstanding, K 126,748
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,930 K
  • EBIT $ -58 M
  • EBITDA $ -58 M
  • 60-Month Beta 0.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.45
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/01/70
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0001 +200.00%
on 12/05/25
0.0400 -99.25%
on 12/18/25
-0.0197 (-98.50%)
since 11/28/25
3-Month
0.0001 +200.00%
on 12/05/25
0.0400 -99.25%
on 12/18/25
-0.0197 (-98.50%)
since 09/30/25
52-Week
0.0001 +200.00%
on 12/05/25
0.0600 -99.50%
on 01/02/25
-0.0013 (-81.25%)
since 12/30/24

Most Recent Stories

More News
ICR Hosts Vaxxinity CEO Mei Mei Hu on the Welcome to the Arena Podcast

ICR , a leading strategic communications and advisory firm, is pleased to announce that Mei Mei Hu, Chief Executive Officer and Co-Founder, Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the...

VAXX : 0.0003 (unch)
Why Shares of Vaxxinity Jumped This Week

Investors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one.

VAXX : 0.0003 (unch)
PFE : 24.90 (-0.36%)
Why Shares of Vaxxinity Soared This Week

Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.

VAXX : 0.0003 (unch)
Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312 Phase 1 Part B Trial for Parkinson’s...

VAXX : 0.0003 (unch)
Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines

Summit is taking place July 26, 2022 from 11:00 AM ET – 3:15 PM ET The White House Summit on the Future of COVID-19 Vaccines live webcast can be accessed...

VAXX : 0.0003 (unch)
Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates

DALLAS, May 09, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic...

VAXX : 0.0003 (unch)
CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq:...

VAXX : 0.0003 (unch)
Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates

DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic...

VAXX : 0.0003 (unch)
Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic...

VAXX : 0.0003 (unch)
Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Investigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at...

VAXX : 0.0003 (unch)

Business Summary

Vaxxinity Inc. is a biotechnology company pioneering a new class of immunotherapeutic vaccines to democratize health. Vaxxinity Inc. is based in DALLAS, Texas.

See More

Key Turning Points

3rd Resistance Point 0.0003
2nd Resistance Point 0.0003
1st Resistance Point 0.0003
Last Price 0.0003
1st Support Level 0.0003
2nd Support Level 0.0003
3rd Support Level 0.0003

See More

52-Week High 0.0600
Fibonacci 61.8% 0.0371
Fibonacci 50% 0.0301
Fibonacci 38.2% 0.0230
Last Price 0.0003
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar